CVS Health Corp.’s shares fell after the drug-store chain cut its earnings forecast for the year in order to pay for two major acquisitions that are central to its strategy of moving beyond retail into becoming a health-care provider as well.
Senate Democrats plan to announce Wednesday that they’ll begin drafting a new comprehensive bill to enhance US economic competition with China and prepare a response in case of Chinese aggression against Taiwan.
The threat of recession is making debt securities a safer bet, while the stock market is yet to price in those risks.
Wolfspeed Inc sees green tech subsidies in the European Union to attract production of semiconductors important for electric cars as on par with what’s on offer in the US.
Welcome to Social Buzz, a daily column looking at what’s trending on social media platforms. I’m Caitlin Fichtel, an editor on Bloomberg’s Breaking News team, which monitors everything from company statements to tweets from some of the most prominent people in the financial world. Here’s your daily look at what the internet is talking about.
The Mexican government is not currently considering giving state oil company Petroleos Mexicanos a capital injection this year to help pay upcoming debt, said Deputy Finance Minister Gabriel Yorio in an interview with Bloomberg News.
Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval.
Turmoil in global labor markets from Covid-19 and technological advances like artificial intelligence are aggravating gender disparity in the global workforce, according to LinkedIn Corp.’s Suzanne Duke.
Starbucks Corp. slumped after reaffirming its guidance despite handily beating sales and profit estimates in the most recent quarter.
Cerevel Therapeutics Holdings Inc. Chief Executive Officer Tony Coles, 62, will step down next month after four years at the helm of the neuroscience drugmaker, which has faced delays in developing new treatments.
